Serum microRNA‑122 for assessment of acute liver injury in patients with extensive skeletal muscle damage
Laboratory Medicine · 2024
DOI: 10.1093/labmed/lmae022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Laboratory Medicine, 2024. Verfasst von Yu Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas MD Anderson Cancer Center Division of Pathology and Laboratory Medicine, Houston, TX, US. Hauptthemen laut MEDLINE: MicroRNAs, Chemical and Drug Induced Liver Injury, Biomarkers. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Background
Serum level of microRNA-122 (miR-122) has been reported as a sensitive diagnostic biomarker for detecting liver injury, comparable to the aminotransferases. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activities are increased in other conditions, such as acute skeletal muscle injury (ASMI). We determined whether miR-122 is nonspecifically increased in patients suffering from ASMI.
Methods
We measured ALT, AST, creatine kinase (CK), and miR-122 in 3 groups: healthy controls (n = 24), patients with ASMI (total n = 29, 11 with recreational drug use and 18 without recreational drug use), and patients with acute liver injury (ALI; n = 14).
Results
Levels of ALT, AST, and CK increased 83%, 97%, and 100% for patients with ASMI and 100% for all 3 enzymes in ALI patients. In contrast, miR-122 increased in 34% of patients with ASMI (44.4% with recreational drug use and 18.2% without recreational drug use) and 100% of ALI patients. In 2 drug-induced liver injury cases, miR-122 increased about 12-24 hours before ALT and AST.
Conclusion
Recreational drug misuse is associated with both rhabdomyolysis and drug-induced liver injury (DILI). The traditional liver function markers AST and ALT were nonspecifically increased in the majority of patients with ASMI. miR-122 is only increased in patients at risk for DILI and demonstrates superior specificity for liver injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Texas MD Anderson Cancer Center Division of Pathology and Laboratory Medicine, Houston, TX, US.
- University of California San Francisco - Laboratory Medicine, San Francisco, CA, US.
- Department of Medicine, University of California San Francisco, San Francisco, CA, US.
- University of California San Francisco Medical Center at Parnassus - Laboratory Medicine, San Francisco, CA, US.
ORCID-Profile: Yu Zhang, Kara Lynch
Zitieren
APA
Zhang, Y., Ong, C. M., Lynch, K., Waksman, J., & Wu, A. H. B. (2024). Serum microRNA‑122 for assessment of acute liver injury in patients with extensive skeletal muscle damage. Laboratory Medicine. https://doi.org/10.1093/labmed/lmae022
Vancouver
Zhang Y, Ong CM, Lynch K, Waksman J, Wu AHB. Serum microRNA‑122 for assessment of acute liver injury in patients with extensive skeletal muscle damage. Laboratory Medicine. 2024. doi:10.1093/labmed/lmae022
BibTeX
@article{Zhang2024,
author = {Zhang, Yu and Ong, Chui Mei and Lynch, Kara and Waksman, Javier and Wu, Alan H B},
title = {Serum microRNA‑122 for assessment of acute liver injury in patients with extensive skeletal muscle damage},
journal = {Laboratory Medicine},
year = {2024},
doi = {10.1093/labmed/lmae022}
}
EUVIMED